Anas Hamad: Medication Adherence and Treatment Persistence Following the Switch From VKAs to DOACs
Anas Hamad, Deputy Chief of Drug Supply Department, Head of Pharmacy Research Center, Corporate Pharmacy Executive Office at Hamad Medical Corporation, Lead of Health Technology Assessment and Innovation Regulation National Program at Ministry of Public Health – Qatar, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in BMC Cardiovascular Disorders, adding:
“Pleased to share our latest publication ‘Medication Adherence and Treatment Persistence Following Switching from Vitamin K Antagonists to Direct Oral Anticoagulants: a Systematic Review’ in the BMC Cardiovascular Disorders journal by Springer Nature.
As the use of DOACs continues to expand, understanding what happens after patients switch from traditional vitamin K antagonists is essential. The clinical advantages of DOACs can only be fully realized when the patient remains adherent to and persistent with their treatment.
Our article included 16 studies and found generally encouraging levels of objectively measured adherence following switching. 76%–97.5% of patients achieved a proportion of days covered (PDC) of 80% or higher.
However, treatment persistence was considerably more variable, ranging from 54% to 94%, highlighting an important opportunity for continued patient monitoring and adherence support.
Poor INR control and low time in therapeutic range were among the most frequently reported factors for switching from VKAs to DOACs.
Importantly, the variability in how adherence and persistence were defined and measured across studies reinforces the need for more standardized approaches to evaluating anticoagulation outcomes and for continued adherence-support strategies even after transitioning patients to DOAC therapy.
Sincere thanks to the whole research team, especially Mohammed Alfaqeeh and Ahmed Riyadh Alaqab, for their valuable contributions, dedication, and teamwork in this study.”
Title: Medication adherence and treatment persistence following switching from vitamin K antagonists to direct oral anticoagulants: a systematic review
Authors: Ahmed Alaqab, Mohammed Alfaqeeh, Rosnani Hashim, Maali Mustafa, Anas Hamad, Niveen M. E. Abu-Rmeileh, Rizky Abdulah, Sofa D. Alfian
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience